JPRN-UMIN000025798已完成未知
Randomized, double-blind, crossover, confirmation test of cold sensitivity and blood flow improving function by ingesting test food. - Randomized, double-blind, crossover, confirmation test of cold sensitivity and blood flow improving function by ingesting test food.
CPCC Company Limited0 个研究点目标入组 25 人开始时间: 2017年1月23日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable(—)
- 性别
- Female
入选标准
- 未提供
排除标准
- •1) Subjects who were diagnosed as chilliness by medical doctor. 2) Subjects who ingest medicines and/or supplement regularly for improving fatigue, blood flow, cold sensitivity or stress. 3) Pregnant or possibly pregnant women, or lactating women. 4) Subjects who have previous and/or current medical history of serious disease in heart, liver, kidney and/or digestive trucks. 5) Subjects who excessive alcohol intake. 6) Subjects who have extremely irregular life rhythms, and subjects who have midnight work or irregular shift work. 7) Subjects who have previous medical history of drug and/or food allergy. 8) Subjects who are participating the other clinical tests of medicines or foods. Subjects who participated other clinical tests of medicines or foods within 4-weeks prior to the current study. 9) Subjects who donated over 200mL blood and/or blood components within a month to the current study. 10) Subjects who donated over 400mL blood within the last four months to the current study. 11) Subjects who will be collected over 800mL blood and/or blood components when, the sampling amounts within the last twelve months are adding to the planned sampling amounts of this study. 12) Subjects who have been determined ineligible by principal investigator or sub-investigator.
研究者
相似试验
进行中(未招募)
不适用
Double-blind, double-dummy, randomized, crossover, multicentre phase IV clinical study comparing the effect of Ursofalk® 500 mg tablets od versus Ursofalk® 250 mg capsules od on liver enzyme parameters in the treatment of primary biliary cirrhosis - Ursofalk® tablets versus Ursofalk® capsules in the treatment of PBCEUCTR2008-001524-31-DEDr. Falk Pharma GmbH74
进行中(未招募)
1 期
Double-blind, double-dummy, randomized, crossover, multicentre phase IV clinical study comparing the effect of Ursofalk® 500 mg tablets od versus Ursofalk® 250 mg capsules od on liver enzyme parameters in the treatment of primary biliary cirrhosis - Ursofalk® tablets versus Ursofalk® capsules in the treatment of PBCTreatment of primary biliary cirrhosisMedDRA version: 9.1Level: LLTClassification code 10036680Term: Primary biliary cirrhosisEUCTR2008-001524-31-NLDr. Falk Pharma GmbH74
进行中(未招募)
不适用
Randomised, double-blind, double-dummy, cross-over trial comparing salmeterol 50 µg b.i.d. via a novel DPI versus salmeterol 50 µg b.i.d. via Diskus in adult patients with persistent asthma - Inhalation Study Salmeterol DPIAdult patients with stable persistent asthmaMedDRA version: 9.1Level: LLTClassification code 10049106Term: Asthma chronicEUCTR2006-006793-26-DEmibe GmbH Arzneimittel
进行中(未招募)
不适用
Randomised, double-blind, double-dummy, cross-over trial comparing a novel DPI with formoterol versus Oxis Turbohaler 12 µg in patients with stable persistent asthma - Inhalatorstudie Formoterol DPIEUCTR2006-001141-34-DEABOpoint GmbH
进行中(未招募)
不适用
Central randomized, double-blind, crossover, multicenter clinical trial of Betametasone and placebo in children with ataxia teleangectasia - FMPS?30094ataxia teleangectasiaMedDRA version: 9.1Level: SOCClassification code 10029205Term: Nervous system disordersEUCTR2008-001185-91-ITAZIENDA OSPEDALIERA SENESE
